Trial intelligence / Profile preview

Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas

NCT07123116Not yet recruiting

Sponsor
Jiangsu Famous Medical Technology
Start
Aug 2025
Primary completion
Nov 2028
Modality
Small Molecules
Countries
1
01

Overview

Randomised, double-blind trial in Colorectal Adenoma (CRA) comparing Shenbai Granules with Placebo (2 arms). Primary endpoint: Detection rate of metachronous colorectal adenoma at 3 years. Planned start Aug 2025; status: not yet recruiting.

02

Drugs

Shenbai Granules
03

Conditions

Colorectal Adenoma (CRA)

Beyond the preview

Go deeper on NCT07123116.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07123116.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call